dc.contributor.author | Tiu, C | |
dc.contributor.author | Shinde, R | |
dc.contributor.author | Pal, A | |
dc.contributor.author | Biondo, A | |
dc.contributor.author | Lee, A | |
dc.contributor.author | Tunariu, N | |
dc.contributor.author | Jhanji, S | |
dc.contributor.author | Grover, V | |
dc.contributor.author | Tatham, K | |
dc.contributor.author | Gruber, P | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | De Bono, JS | |
dc.contributor.author | Nicholson, E | |
dc.contributor.author | Minchom, AR | |
dc.contributor.author | Lopez, JS | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-09-13T09:10:37Z | |
dc.date.available | 2022-09-13T09:10:37Z | |
dc.date.issued | 2021-11-01 | |
dc.identifier.citation | J Immunother Precis Oncol, 2021, 4 (4), pp. 189 - 195 | |
dc.identifier.issn | 2666-2345 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5445 | |
dc.identifier.eissn | 2590-017X | |
dc.identifier.eissn | 2590-017X | |
dc.identifier.doi | 10.36401/JIPO-21-9 | |
dc.description.abstract | INTRODUCTION: Immune checkpoint inhibitors (ICIs) are increasingly a standard of care for many cancers; these agents can result in immune-related adverse events (irAEs) including fever, which is common but can rarely be associated with systemic immune activation (SIA or acquired HLH). METHODS: All consecutive patients receiving ICIs in the Drug Development Unit of the Royal Marsden Hospital between May 2014 and November 2019 were retrospectively reviewed. Patients with fever ≥ 38°C or chills/rigors (without fever) ≤ 6 weeks of commencing ICIs were identified for clinical data collection. RESULTS: Three patients met diagnostic criteria for SIA/HLH with median time to onset of symptoms of 10 days. We describe the clinical evolution, treatment used, and outcomes for these patients. High-dose steroids are used first-line with other treatments, such as tocilizumab, immunoglobulin and therapeutic plasmapheresis can be considered for steroid-refractory SIA/HLH. CONCLUSION: SIA/HLH post ICI is a rare but a potentially fatal irAE that presents with fever and a constellation of nonspecific symptoms. Early recognition and timely treatment are key to improving outcomes. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 189 - 195 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Innovative Healthcare Institute | |
dc.relation.ispartof | J Immunother Precis Oncol | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | HLH | |
dc.subject | fever | |
dc.subject | immune checkpoint inhibitor | |
dc.subject | immune-related adverse events | |
dc.subject | systemic immune activation | |
dc.subject | toxicity | |
dc.title | A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-07-09 | |
dc.date.updated | 2022-09-13T09:09:12Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.36401/JIPO-21-9 | |
rioxxterms.licenseref.startdate | 2021-11-01 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35665022 | |
pubs.issue | 4 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Cell Death and Immunity | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/The Adult Drug Development Unit at the ICR and the RM | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Early Phase Drug Development | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/21/22 Starting Cohort | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.36401/jipo-21-9 | |
pubs.volume | 4 | |
icr.researchteam | Cell Death and Immunity | |
icr.researchteam | Clinical Pharmacology | |
icr.researchteam | PrCa Targeted Therapy | |
icr.researchteam | Adult DDU ICR & RM | |
icr.researchteam | Early Phase Drug Develop | |
dc.contributor.icrauthor | Tiu, Crescens | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | De Bono, Johann | |
dc.contributor.icrauthor | Minchom, Anna | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: A Wolf in Sheeps Clothing Systemic Immune Activation Post Immunotherapy.pdf | |